Doctor of Philosophy in Interdisciplinary Oncology (PhD)
The Interdisciplinary Oncology program (IOP) is a graduate program designed to appeal to a broad range of students interested in cancer research. IOP offers advanced study and research in a variety of fields relating to oncology. Those fields include: molecular and cellular biology, genetics, biophysics, bioinformatics, pharmaceutical sciences, radiological sciences, immunology, molecular pathology, sociobehavioral studies, epidemiology and health economics. The goal of the program is to provide graduate students from diverse backgrounds, with an education in a number of disciplines relating to oncology, and to provide training opportunities for intensive training in specialized aspects of cancer research. For more than ten years, the program has been training the next generation of cancer research leaders.
What makes the program unique?
IOP integrates the diverse areas of oncology by offering two required courses which provide an interdisciplinary perspective on oncology in a form that is accessible to students from diverse backgrounds. The elective courses provide intensive training in one or more subjects specific to the student's research, and also gives the student an opportunity to gain expertise in other disciplines that have potential for synergy with their primary specialization. Students have access to clinicians and university faculty through the world-renowned BC Cancer Agency, to get a practical perspective on oncology treatments and outcomes. An innovative rotation course is a unique option for students to gain hands-on experience by rotating through specialty laboratories and by shadowing clinicians.
Most IOP supervisors reside off-campus at the BC Cancer Research Centre, the Prostate Centre at Vancouver General Hospital or other hospital-related buildings.
Students must secure a supervisor before they can be admitted into the program. As well, they must meet the minimum admission requirements set out by Graduate and Post-doctoral Studies at UBC.
CV, Official transcripts, three letters of reference, Official English exam scores (if required)
TOEFL (ibT) Overall Score Requirement
IELTS Overall Score Requirement
Supervisor commitment required prior to application?
Prior degree requirements
A B.Sc is the minimum requirement.
Deadline to submit online application. No changes can be made to the application after submission.Transcript Deadline
Deadline to upload scans of official transcripts through the applicant portal in support of a submitted application. Information for accessing the applicant portal will be provided after submitting an online application for admission.Referee Deadline
Deadline for the referees identified in the application for admission to submit references. See Letters of Reference for more information.
January 2020 Intake
Application Open Date19 June 2019
May 2020 Intake
Application Open Date20 June 2019
September 2020 Intake
Application Open Date21 June 2019
All students who secure a supervisor and who are enrolled in the program will be paid a minimum stipend of $24,300/year.
7 students graduated between 2005 and 2013: 1 is in a non-salaried situation; for 0 we have no data (based on research conducted between Feb-May 2016). For the remaining 6 graduates:
Sample Employers in Higher EducationQueen's University Belfast
University of Toronto
Sample Employers Outside Higher EducationJohnson and Johnson Inc.
Princess Margaret hospital
RepliCel Life Sciences Inc.
BC Cancer Agency
Sample Job Titles Outside Higher EducationSenior Scientist
PhD Career Outcome SurveyYou may view the full report on career outcomes of UBC PhD graduates on outcomes.grad.ubc.ca.
DisclaimerThese data represent historical employment information and do not guarantee future employment prospects for graduates of this program. They are for informational purposes only. Data were collected through either alumni surveys or internet research.
Tuition / Program Costs
|Fees||Canadian Citizen / Permanent Resident / Refugee / Diplomat||International|
|Installments per year||3||3|
|Tuition per installment||$1,665.26||$2,925.58|
|Tuition per year|
(plus annual increase, usually 2%-5%)
|Int. Tuition Award (ITA) per year (if eligible)||$3,200.00 (-)|
|Other Fees and Costs|
|Student Fees (yearly)||$930.14 (approx.)|
|Costs of living (yearly)||starting at $16,884.10 (check cost calculator)|
All fees for the year are subject to adjustment and UBC reserves the right to change any fees without notice at any time, including tuition and student fees. Tuition fees are reviewed annually by the UBC Board of Governors. In recent years, tuition increases have been 2% for continuing domestic students and between 2% and 5% for continuing international students. New students may see higher increases in tuition. Admitted students who defer their admission are subject to the potentially higher tuition fees for incoming students effective at the later program start date. In case of a discrepancy between this webpage and the UBC Calendar, the UBC Calendar entry will be held to be correct.
Completion Rates & Times
Upcoming Doctoral Exams
Monday, 9 December 2019 - 12:30pm - Dorothy Lam Boardroom, BC Cancer Research Centre, 675 West 10th Ave, Vancouver, V5Z 1L3
Wednesday, 11 December 2019 - 9:00am - 8th Floor Seminar Room, BC Cancer Research Centre, 675 West 10th Ave, V5Z 1L3
Friday, 13 December 2019 - 12:30pm - Dorothy Lam Boardroom, BC Cancer Research Centre, 675 West 10th Ave, V5Z 1L3
This list shows faculty members with full supervisory privileges who are affiliated with this program. It is not a comprehensive list of all potential supervisors as faculty from other programs or faculty members without full supervisory privileges can request approvals to supervise graduate students in this program.
Aparicio, Samuel (Breast cancer, genome sequencing )
Bally, Marcel Bertran (Pancreas centre)
Baumbusch, Jennifer (long-term residential care, family caregiving, Intellectual Disability, nursing care of older adults )
Benard, Francois (Medical isotopes Radioisotopes Nuclear Medicine Cancer Imaging Molecular imaging of cancer Radionuclide therapy, Cancer division, radiology, pancreas centre)
Bennewith, Kevin (Oncology; Molecular Pathology & Cell Biology; Cancer research; Solid tumour microenvironment; Hypoxia; Metastasis research; Pre-metastatic niche; Targeting hypoxic tumour cells in therapy; Radiation biology)
Brooks-Wilson, Angela (human genetics, cancer genetics, cancer families, longevity, Super seniors, genetic susceptibility)
Brown, Carolyn Janet (Epigenetic control of gene expression, X-chromosome inactivation, Long non-coding RNAs, XIST RNA, Genes escaping X-chromosome inactivation, DNA methylation)
Burgess, Michael (Public deliberation, Health Policy, Science Policy, Deliberative Democracy)
Buttyan, Ralph (Kidneys, Urinary System, Benign Bladder Dysfunctions)
Campbell, Kristin (exercise physiology, physical function, oncology, biomarkers)
Cox, Michael (genetic testing, experiences of hereditary risk, social and ethical implications of genetics, interpersonal and family communication, qualitative research, narrative and story, Prostate cancer)
Daugaard, Mads (Cancer biology, Glycobiology, DNA damage response pathways, Cancer therapy, Cancer diagnostics, Stress signalling in cancer, Immunotherapy)
Dedhar, Shoukat (molecular biology, molecular biology as it relates to disease; developing new theraputics for cancer; how brain cells (neurons)make connections, therapeutics for cancer; molecular genetics and cancer; medical research, cancer, inflammatory diseases, cariovascular diseases, Cellular proteins, extracellular martrix, integrins, signal transduction, calreticulin, protein kinase, gene expression, cell differentiation)
Eaves, Constance Jean (Normal and leukemic stem cells, normal and malignant breast stem cells)
Garnis, Catherine (Cancer biology; Tumor progression; Oral premalignant lesions; Head and neck cancer; RNA biology, microRNAs; Alternative splicing; Biomarkers)
Gleave, Martin (Infectious diseases, interdisciplinary oncology, prostate)
Guns, Emma (pharmacology, ADMET, drug discovery, mass spectrometry, natural products, cancer cell biology, steroidogenesis in oncology, hormone receptor targeting and pathway analysis (pharmacodynamics), extracellular vesicles in cancer cell communication)
Hieter, Philip (Molecular biology of eukaryotic chromosome transmission )
Hirst, Martin (Epigenomics)
Holt, Robert (Immunogenetics, Metagenomics - Infectious agents in Cancer, Cancer Genomes, Neurobiology, DNA Sequencing)
Howard, Fuchsia (health service needs of vulnerable, high-risk survivors of acute life-threatening illness, specifically, cancer survivors and survivors of critical illnesses; hereditary cancer prevention and risk management and psychosocial and ethnocultural factors that shape health and illness experiences)
Huntsman, David (hereditary cancer, molecular pathology, cancer biomarkers, Pancreas centre)
Jiang, Xiaoyan (Basic and translational leukemia research, Leukemic stem cell biology , Gene regulation , Drug resistance , Proteomics, Immunotherapy)
Recent Doctoral Citations
- Dr. Daiana Diamantina Becker dos Santos
"Dr. Becker dos Santos discovered that essential genes for human fetal lung development are being reactivated in lung cancer. By exploring the downstream consequences of such reactivation, she identified a novel biomarker for lung cancer aggressiveness and patient outcome." (May 2019)
- Dr. Jamie Simin Emma Yu
"Myxoid liposarcoma is a type of cancer that predominantly affects young adults. Dr. Yu's doctoral studies examined the role of how a mutant protein functions as the main cause of myxoid liposarcoma. Her research uncovered a new function of the mutant protein that can form the basis of future treatment strategies for this disease." (May 2019)
- Dr. Yi-Jye Chern
"Dr. Chern studied the chemotherapy resistance mechanisms in colon cancer. She found that HSP47 proteins promote drug resistance, and the interaction between SPARC and GRP78 proteins enhances the stress level and increases cell death in cancer cells under chemotherapy. Her findings provide insights into overcoming chemoresistance in colon cancer." (May 2019)
- Dr. Mannan Nouri
"Dr. Nouri showed that prostate cancer cells treated with hormone therapy might undergo a transformation to a more stem-like cell to promote therapy escape and disease progression. By capturing, analyzing, and targeting key pathways in these cells, he explored a pre-clinical therapeutic regimen that could potentially prevent prostate cancer recurrence." (May 2019)
- Dr. Stephen Yiu Chuen Choi
"Dr. Choi proposed a new hypothesis suggesting that altered cancer metabolism and secretion of lactic acid dampens the anticancer immune response. His work helps us better understand the role of lactic acid in multiple cancer-promoting processes and could lead to an effective treatment strategy for advanced prostate cancer and other malignancies." (May 2018)